• China Immunotech

  Participated · Series B · Oct 2021

  BriSTAR Immunotech, founded in March 2018, focuses on development and industrialization of innovative cell‑therapy drugs using two proprietary platforms: STAR‑T and enTCR‑T. The company has diversified pipelines targeting hematologic malignancies, solid tumors and viral infections and has established cooperation in more than ten First‑in‑Human clinical studies with domestic hospitals. Early IIT clinical data show positive safety and effectiveness and the work has received recognition from Science Translational Medicine, ASH and EHA. Management and scientific leadership include founder Professor Lin Xin and co‑founder Dr. Xueqiang Zhao, and the company says it has a high‑level international team and mature process and quality control platforms. Planned use of new capital includes clinical trials for the dual‑target hematoma STAR‑T project, development and clinical research of solid‑tumor STAR‑T pipelines, and steps toward industrialization to scale product manufacturing.

No current team members are available.